Back
For best output, select "Paper Size" as "A4" and "Margin" as "0" or "None".
To save or print to PDF, please select Print Destination > Save as PDF, enable Background Graphics under "More Settings", then click "Save".
During the congress, E-Posters will be accessible to all participants on the congress website 24/7, as well as in the E-poster stations in the congress center.
Preparing your E-Poster
Please review the E-Poster format requirements carefully when preparing your E-Poster. Should your E-Poster not meet the mentioned requirements, it may not be displayed as described above.
E-Poster Submission Deadline
Please prepare and upload your E-Poster no later than March 14, 2026 11.59PM CET. After this date, you will no longer be able to prepare and upload your E-poster and it will not be displayed and accessible on the congress website.
Please follow the instructions below to input your abstract title.
Abstract titles should be brief and reflect the content of the abstract.
Recent studies have identified circulating autoantibodies against slit diaphragm proteins, such as nephrin and podocin, in a subset of patients with nephrotic syndrome. However, the clinical implications of these antibodies, particularly in adult-onset cases, remain unclear. This study aimed to elucidate the prevalence and clinical significance of anti-nephrin and anti-podocin antibodies across various pathological types of nephrotic syndrome.
We retrospectively analyzed 114 adult Japanese patients with biopsy-proven nephrotic syndrome admitted to Kanazawa Medical University Hospital, including minimal change nephrotic syndrome (MCNS, n = 47), focal segmental glomerulosclerosis (FSGS, n = 14), PLA2R-associated membranous nephropathy (PLA2R-MN, n = 40), and NELL1-associated MN (NELL1-MN, n = 13). Serum antibodies against nephrin and podocin were quantified by enzyme-linked immunosorbent assay (ELISA). Cutoff values were defined as the maximum titer among healthy controls (n = 40) plus a small margin. Patients with MCNS and FSGS were further classified into antibody-positive and -negative groups for comparison of clinical characteristics and outcomes.
The prevalence of anti-nephrin antibodies was 38.3% in MCNS, 14.2% in FSGS, 2.5% in PLA2R-MN, and 7.7% in NELL1-MN. Anti-podocin antibodies were detected in 10.6%, 7.1%, 7.5%, and 30.8% of these groups, respectively. Among MCNS and FSGS patients, the antibody-positive group exhibited higher baseline serum creatinine (1.03 vs. 0.91 mg/dL, P < 0.05) and greater proteinuria (12.7 vs. 10.3 g/gCr, P < 0.05) compared with the antibody-negative group. No significant differences were observed in remission rates (JSN-ICR2, JSN-ICR1, JSN-CR, or KDIGO-CR) or time to first relapse between the two groups. However, steroid dependence was significantly more common in antibody-positive cases (80% vs. 44.4%, P < 0.05).
Anti-nephrin antibodies were predominantly observed in MCNS and FSGS, whereas anti-podocin antibodies were also relatively frequent in membranous nephropathy. Antibody-positive patients had greater baseline proteinuria and worse renal function and were more likely to develop steroid dependence.
